Unilever, which has been beneath fireplace from some traders for the group’s underperforming share value, confirmed the strategy a few potential acquisition of the enterprise in an announcement on Saturday.
“GSK Client Healthcare is a frontrunner within the engaging client well being area and can be a robust strategic match as Unilever continues to re-shape its portfolio,” it mentioned.
“There might be no certainty that any settlement will likely be reached.”
GSK declined to touch upon the strategy.
Earlier, Britain’s Sunday Occasions mentioned the Unilever bid for the enterprise made late final yr was value roughly 50 billion kilos, and had been rejected as too low by GSK and Pfizer, which owns a minority stake within the division.
The strategy by Unilever, which owns manufacturers comparable to Dove cleaning soap and Marmite, for Glaxo’s portfolio of family manufacturers together with Panadol painkillers and Sensodyne toothpaste was understood to have been unsolicited, it added.
Unilever’s bid didn’t embody any takeover premium or recognition of synergies, the newspaper mentioned, including that it was not clear whether or not the group would make a better supply.
Unilever has come beneath strain from traders after underperforming rivals comparable to Procter & Gamble.
Chief Govt Alan Jope lately obtained right into a spat with British fund supervisor Terry Smith, who criticised the group for selling sustainability credentials on the expense of efficiency.
Brokerage Jefferies final yr put a valuation for the entire client unit at 45 billion kilos.
Deutsche Financial institution analysts mentioned in June 2021 that any takeover bid for GSK’s client property value greater than 45 billion kilos can be “eye-watering”.
Unilever has beforehand shot down recommendations that it was available in the market for giant offers. Jope has mentioned he was solely excited about small, bolt-on acquisitions in fast-growing areas comparable to luxurious health and beauty and wellness.